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Preface — About This Book
This book is intended for a law school survey course on food and drug regulation. It covers the Food and Drug Administration’s (FDA’s) regulation of food, food
additives, dietary supplements, drugs, animal drugs, medical devices, combination
products, biologics, HCT/Ps (human cells, tissues, and cellular and tissue-based
products), cosmetics, color additives, and tobacco products. It also covers administrative procedure, regulation of research, FDA enforcement, federal preemption,
and regulation of imports. It presents more limited material on related areas regulated primarily by other agencies.1 In addition to covering this substantive material,
the book w
 ill introduce you to the process of understanding a complex statute, its
implementing regulations, and related enforcement policies.
The book’s coverage is not intended to be comprehensive. Several existing books
present treatise-level coverage and even those cannot cover FDA’s regulatory programs comprehensively. This book instead focuses on core aspects of selected FDA
regulatory programs in the areas of food and medical products.2
Food and drug regulation is primarily a statutory and regulatory subject. Accordingly, this book relies on a different set of documents and a different style of presen
tation than a typical casebook. The book emphasizes guided reading of the Federal
Food, Drug, and Cosmetic Act, related statutes, FDA regulations, and Federal Register documents. Cases are presented primarily when they involve major issues of
statutory interpretation, are historically significant, or are in one of the areas — 
such as federal preemption — where case law plays a major role in the overall regulatory scheme. Cases are also included where they provide a concise discussion of a
regulatory program or a useful illustration of a concept.
This book is designed to work as a set with the accompanying Statutory & Regulatory Supplement (Supplement). The Supplement is available f ree, in PDF format,
on this book’s page of the Carolina Academic Press website.3 The statutes and regulations in the Supplement have been aggressively edited, like the cases in a typical

1. These include USDA-regulated foods (meat, eggs, poultry, and fish of the order siluriformes
(catfish and related species)), agricultural biotechnology, alcohol, controlled substances, and veterinary biologics.
2. The main categories the book does not address are animal food and feed, radiation-emitting
products, and medical gases.
3. 
See https://cap-press.com / books /isbn /9781531004453/Food-a nd-Drug-Regulation.
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law school casebook, to emphasize those aspects that are most important to a general understanding of the subject.

Structure of the Book
The book is organized around the structure of the Federal Food, Drug, and Cosmetic Act of 1938 (FFDCA) and the relevant portion of the Public Health Serv ices
Act (PHSA).4 This means that Chapter IV products (food, food additives, and dietary
supplements), Chapter V products (drugs, animal drugs, medical devices, and combination products), and PHSA products (biologics and HCT/Ps) are each grouped
together. The single-product-category chapters — Chapter VI (cosmetics), Chapter
VII (color additives), and Chapter IX (tobacco products) — are then included in a
final, catch-a ll group. Parts I, II, and VII of the book address cross-cutting issues,
while Parts III, IV, V, and VI address the four groups of individual product categories. Part VIII contains the appendices.
Part I of the book introduces the basic structure of FDA and the FFDCA. Within
Part I, Chapter 1 addresses the structure of the agency and the product categories
set out in the FFDCA. Chapter 2 addresses administrative procedure. It contains
material on administrative procedure generally and on administrative procedure
specific to FDA.
Part II of the book addresses regulation of research, marketing authorization,
and background regulatory requirements associated with marketing authorization.
This Part emphasizes those aspects of research, marketing authorization, and
background requirements that are similar across multiple product categories.
Within Part II, Chapter 3 addresses regulation of research. It focuses on FDA
regulation of human-subject research. Chapter 4 addresses marketing authorization.
It contains material on pathways to market, designations, and access before
market authorization. Chapter 5 addresses background requirements associated
with marketing authorization. It contains information on production-process
requirements, labeling requirements, establishment registration requirements, user
fees, and postmarket requirements.
Part III of the book addresses those products regulated primarily 
under
Chapter IV of the FFDCA. Chapter 6 addresses food, Chapter 7 addresses food
additives, and Chapter 8 addresses dietary supplements. Chapter 9 does not address
a single product category. Instead, it contains material on label claims for the two
Chapter IV categories — food and dietary supplements — for which label-claim

4. Please note that this book uses: Roman numerals when referring to parts of this book (Part V);
Arabic numerals when referring to parts of the CFR (21 C.F.R. Part 5); Arabic numerals when referring to chapters of this book (Chapter 5); and roman numerals when referring to chapters of the
FFDCA (Chapter V).
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issues arise. Label claims receive a separate chapter to avoid presenting duplicative
material in the e arlier chapters on food and dietary supplements.
Part IV of the book addresses 
t hose products regulated primarily 
under
 hapter V of the FFDCA. Chapter 10 addresses drugs, Chapter 11 addresses animal
C
drugs, Chapter 12 addresses medical devices, and Chapter 13 addresses combination products.
Part V of the book addresses those products regulated primarily under the PHSA.
Chapter 14 addresses those aspects of biological products regulated primarily by the
PHSA.5 Chapter 15 addresses HCT/Ps.
Part VI of the book addresses those products regulated under the FFDCA Chapters VI, VII, and IX. Chapter 16 addresses cosmetics, Chapter 17 addresses color
additives, and Chapter 18 addresses tobacco products.
Part VII returns to cross-cutting issues of the type addressed in Parts I and II.
Chapter 19 addresses FDA enforcement, Chapter 20 addresses federal preemption,
and Chapter 21 addresses regulation of imports.
Part VIII is an appendix recommending further reading. Its focus is on books
rather than academic articles, with a particular emphasis on items available as
audiobooks (a wonderful help to the busy lawyer during commuting or exercise).
It includes both law-specific reading and material on scientific, technological, and
industrial developments relevant to food and drug regulation.
For a description of the structure of individual chapters, see “Introduction to this
Book” in Chapter 1, Part A.

Citation Format and Editorial Approach
I have aggressively edited the documents that I have excerpted in this book. My
goal in doing this is to emphasize those aspects of the excerpted documents that are
most relevant to basic goal of this book: presenting an approachable overview of the
basic structure of food and drug regulation.
Citations in this book conform generally to the 20th edition of The Bluebook:
A Uniform System of Citation. Significant exceptions are the following:
I have cited Federal Register documents in a format that emphasizes the date of
publication and type of document, rather than document title. I have done this for
two reasons. First, t hese documents frequently contain cumbersome multipart titles
that — despite their length — are of only limited value in describing the document’s

5. As you w ill see later, all products meeting the statutory definition of biological product,
PHSA § 351(i)(1), also meet the statutory definition of drug, FFDCA § 201(g)(1). Accordingly,
much of this chapter of the book is focused on the relationship between FDA’s biologics division
(transferred from the National Institute of Health to FDA in the 1970s) and FDA’s drugs division.
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content. Second, the administrative rulemaking process typically results in multiple
documents with very similar titles. This book uses the format below, which I believe
w ill help you distinguish more clearly between the different documents cited:
[date of publication in YYYY-MM-DD format] [abbreviated agency name
(FDA, USDA, EPA, etc.)] [type of document (notice, proposed rule, final rule,
etc.)], [title or shortened title] [FR volume #] Fed. Reg. [FR page #]
Within quoted original sources, the original citation format is retained except
where I have determined that a modification w
 ill increase clarity or make the document more readable.
Also within quoted original sources, I have made the following omissions without any indication in the text:
• omitted most citations and footnotes, retaining only those that I believe w ill be
of use to the reader (retained footnotes have their original numbering);
• omitted most quotation marks in situations where courts are simply quoting
the language of prior judicial opinions as part of their own sentences (in the
standard style of judicial opinion-w riting);6
• modified the format of some retained citations to conform to the style of this
book;
• replaced the use of a series of asterisks (common in older documents) with the
modern use of three-dot or four-dot ellipses, as appropriate;
• omitted text from the part of an excerpted document that precedes the quoted
language.
Where I have omitted text from a quoted source, I have used three-dot ellipses to
indicate omissions of less than a sentence and four-dot ellipses to indicate omissions
of a full sentence or more.
Within quotations and excerpts referencing the FFDCA or the PHSA, I have
replaced references to U.S. Code section numbers with references to the corresponding FFDCA section numbers, following the standard approach in this book. Where
I have done this, I have used the notation “[FFDCA §]” to indicate the change.
One final editorial convention bears emphasis. Both the FFDCA and the PHSA
are phrased in terms of authorities granted to, and obligations imposed upon,
“the Secretary” — meaning the Secretary of Health and Human Services — rather
than FDA. See FFDCA § 201(d). The Secretary of Health and Human Services,
however, has delegated nearly all of the authority to administer these statutes to
the Commissioner of Food and Drugs. See FDA Staff Manual Guides, Volume

6. This is necessary to facilitate omission of citations to the quoted documents, with the aim of
making t hose excerpts more readable. I have done this only in excerpts, not within the text of the
book. Even within excerpts, I have never intentionally omitted quotation marks from sources other
than judicial opinions.
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II — Delegations of Authority § 1410.10 (Effective Date: August 26, 2016). To
make textual descriptions of statutory language more readable, I have generally
substituted “FDA” for “the Secretary” in describing the language of the statute. This
means that:
• In places where the FFDCA grants “the Secretary” authority to take a particular action, I typically describe it as granting “FDA” such authority.
• In places where the FFDCA requires “the Secretary” to take some action, I typically describe it as requiring “FDA” to take such action.
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Chapter 1

Agency Structure and
Product Categories
A. Introduction
1. I ntroduction to This Casebook
As noted in the Preface, this book is designed to work as a set with the accompanying Statutory & Regulatory Supplement (Supplement).1 The statutes and regulations in the Supplement have been aggressively edited, like the cases in a typical law
school casebook, to emphasize t hose aspects that are most important to a general
understanding of the subject.

Primary Document Types
The primary document types included in this book and its Supplement are:
codified statutory materials, calendar-based statutory materials, codified regulatory materials, calendar-based regulatory materials, judicial decisions, formal
agency guidance, and agency website materials. Each of these document types is
explained below. Students new to regulatory work often wonder about the relationship between statutes and regulations, and between calendar-based and codified
materials. That is addressed in more detail further below.
• Codified statutory materials. These are the U.S. statutes as collected and orga
nized into the 54 Titles of the United States Code (USC). This book deals primarily with material from Title 21 — Food and Drugs. It also addresses some
material from other titles, including Title 5 — Government Organization and
Employees, Title 7 — Agriculture, Title 15 — Commerce and Trade, Title 18 — 
Crimes and Criminal Procedure, Title 35 — Patents, and Title 42 — The Public
Health and Welfare.
The Federal Food, Drug, and Cosmetics Act of 1938 (FFDCA), as amended, is
codified in Chapter 9 of Title 21. The Public Health Serv ices Act (PHSA), as
amended, is codified in Chapter 6A of Title 42. When referencing these two
statutes, this book follows the standard practice among food-and-drug lawyers
of referring to the section numbers of the amended statutes, rather than the
numbers for the corresponding section of the U.S. Code. The FFDCA section
1. The Supplement is available f ree, in PDF format, on the Carolina Academic Press website.
3
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numbers correspond to the relevant chapters of the statute and are much easier
to remember than the section numbers in the U.S. Code.2
• Calendar-based statutory materials. These are the a ctual statutes as enacted
through the process specified in Article I, Section 7 of the U.S. Constitution.
These are published as Public Laws, with a number corresponding to the relevant session of Congress,3 a hyphen, and a number assigned in ascending order
from the beginning of that congressional session. They are also published in
the U.S. Statutes at Large.
• Codified regulatory materials. These are the regulations (laws promulgated by
executive branch agencies u
 nder delegated statutory authority) of the United
States as collected and organized into the 50 titles of the U.S. Code of Federal
Regulations (CFR). This book deals primarily with material from Title 21 — 
Food and Drugs. It also references some materials from other titles, including
Title 7 — Agriculture, Title 9 — Animals and Animal Products, and Title 16 — 
Commercial Practices.4
• Calendar-based regulatory materials. These are the various documents published in the Federal Register (FR), the official, chronological record of the
executive branch. These include, most importantly, proposed rules for comment and final rules that w ill be codified as part of the CFR. They also include
notices of various matters, including the availability of guidance documents
(which are not themselves published in the FR). Many proposed and final rules
from recent decades include a preamble stating publicly the reasons for the
relevant agency action. But older proposed and final rules rarely contain an
explanatory preamble. Where an explanatory preamble is available, it can be
helpful to read it much as you would read the reasoning of a court decision
(and, at times, with the same healthy dose of skepticism).
• Judicial decisions. These are, of course, the core content of a traditional law
school casebook in a common-law field. B
 ecause food and drug regulation is
a statutory field, they play less of a role h
 ere. In most chapters of this book,
judicial decisions are included when they resolve major issues of statutory
2. For example, when referring to the “Definitions; generally” provision of the statute, the
book w ill refer to FFDCA § 201, rather than 21 U.S.C. § 321. To avoid overwhelming you with
section numbers, parallel citations to the U.S. Code are included in the statutory supplement but
not in the book itself.
3. The 1st Congress sat from March 1789 to March 1791; the 116th Congress sits from
January 2019 to January 2021.
4. Note that title numbers in the CFR sometimes match title numbers in the USC, but sometimes
do not. Title 21 carries the title “Food and Drugs” in both the USC and the CFR. However, CFR
Title 21 includes some regulations based on statutes outside of USC Title 21 (such as the Public
Health Serv ices Act, codified in USC Title 42). In many other regulatory areas, the numbers do
not match at all. For example, the primary statutes administered by the Securities and Exchange
Commission are codified in Title 15 of the USC. However, the regulations of the Securities and
Exchange Commission are codified in Title 17 of the CFR.
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or constitutional interpretation. They are also occasionally included when
they provide a concise summary of a particular aspect of food and drug
regulation. They play a larger role in Chapter 20 on federal preemption.
• Formal agency guidance. T
 hese are the documents published by FDA under
procedures set out in FFDCA § 701(h) and 21 C.F.R. § 10.115 — Good Guidance
Practices. They do not bind FDA or regulated parties, but nonetheless play a
large role in communicating FDA’s expectations to regulated parties.
• Agency website materials. These are simply materials from FDA’s website that do
not qualify as formal agency guidance. In general, this book prefers excerpts
from the other above document types to agency website materials. However,
there are some situations where website materials are available in an area where
other document types are not. At other times, an agency website provides a
more concise and approachable explanation than other document types. In
those situations, website materials are included.
The Relationship between Codified and Calendar-Based Materials
Statutory materials

Regulatory materials

(organized by date)

Statutes promulgated (through
Congress/president interaction)
on a part icu lar date; legislative
history materials

Everyt hing published in federal
register; items that have their
availability announced in federal
register (but themselves made available
online — guidance documents are the
most prominent example)

Codified

The 54 titles of the USC

The 50 titles of the CFR

(organized by
subject matter)

Statutes, but not legislative
history materials, are codified

The regulations promulgated by a final
rule (but not its preamble, and not other
federal register documents) are codified

Calendar-based

Where to Find the Different Document Types
With rare exceptions, the text of codified statutory and regulatory materials is
included only in the Supplement, and not in this casebook. This is done for two
reasons. First, this w ill help you learn the structure of the statute and regulations,
as you w
 ill always see them set out in the order in which they are codified. Second, you w ill find yourself referring repeatedly to the same statutory sections (but
often different subsections) in different parts of the course. You w ill understand
the interactions between these sections and subsections much better when you
return to a page in the Supplement you have read — and ideally begun to mark
up — previously.
In the book itself, you w
 ill find the remaining document types: excerpts of judicial decisions, calendar-based regulatory materials, formal agency guidance, and
agency website materials.
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Structure of Individual Chapters
Most chapters begin by requesting that you read (or review, as appropriate) specific statutory and regulatory sections in the Supplement. The idea behind this is to
allow you to become familiar with the language and structure of the statute itself,
rather than simply reading out-of-context quotations.
Each chapter then contains, under the heading Outline of Regulatory Regime, several charts.5 None of these is intended to be comprehensive, as comprehensive charts
would provide too much detail to be useful. Instead, they are intended to give you a
general sense of the statutory history, statutory structure, and regulatory structure
relevant to the topics addressed in that chapter.
First, a “Timeline of Key Statutes” chart sets out, in chronological order, the
key calendar-based statutory material. The idea is to give you a historical sense of
the times that statutory change has occurred. How much you should focus on this
depends on the style of your professor. If you have a historically minded professor,
this chart w ill serve as a reference point for you as your professor discusses statutory changes over time. If your professor is focused more on current law, you should
spend less time with this chart and more with t hose that follow.
Second, a “Key Statutory Provisions” chart sets out, in numerical order, the key
sections and subsections of codified statutory material. This w ill usually be a longer
(and at times, much longer) list of sections than those you are asked to read.6 This
is likely the most important of the charts included in each chapter. The idea is to
give you an overview of the statutory structure in the relevant area. As your professor discusses current law, this chart should serve as a reference point for you on
the major statutory provisions relevant to the regulatory area you are discussing.
It should also serve as a starting point if you would like to learn more about some
aspect of the area not covered in this book.
Third, a “Key Regulatory Provisions” chart sets out, in numerical order, the key
parts and subparts (and occasionally sections and subsections) of codified regulatory material (in other words, CFR provisions).7 The idea is to give you an overview
of the regulatory structure in the relevant area. The Supplement includes excerpts
from only a small number of these key regulatory provisions. Most are too long, and
too technically detailed, to ask you to read their text in a one-semester course. What
you should understand is that a large portion of the a ctual law relevant to food and
drug regulation is contained in this codified regulatory material. Few practicing
lawyers w
 ill have read large numbers of these provisions in their entirety. However,
it is critical to know, for any particular regulatory area: (1) what codified provisions
exist; (2) where to find them; and (3) what role they play (in relation to statutes and
guidance) in the regulatory scheme.8
5. In addition to, or instead of, the outline at the beginning of the chapter, a few chapters contain a separate Outline of Regulatory Regime section for one or more subtopics.
6. Portions of many, but not all, key statutory provisions are excerpted in the Supplement.
7. This is sometimes a single chart and sometimes two or more charts grouped by subtopic.
8. The legal status of agency guidance is discussed in more detail in Chapter 2.
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As you read each chapter for the first time, you should do no more than skim
these charts to get a general sense of the structure of the laws and regulations relevant to the topic of the chapter. As you begin to review the material at the end of
the semester (or perhaps work on a seminar paper), you may find it helpful to look
back at t hese charts in more detail.
Following these charts, most chapters contain various additional parts, many of
which contain excerpts from relevant documents. All chapters conclude with a “Key
Points” section. This Key Points section is placed at the end of the chapter, as that is
the point where it is likely to be most useful to you. However, you may also find it useful to skip to the relevant Key Points section, and review it briefly, before you begin
reading each chapter — and then to review it again when you reach the chapter’s end.

The Relationship Between Codified and Uncodified Material
(and Why It Is Necessary to Study Both)
Students often wonder why, when codified statutory and regulatory materials are
available, it is nonetheless important to study non-codified materials as well. The
answer is that non-codified materials provide information that is not available in
the codified materials.
For statutory provisions, the U.S. Code is your best source of current law. But if
you want to know when a particular provision was added to — or removed from — 
the codified law, the individual statutes passed by Congress are your best source of
information. Additionally, individual statutes w
 ill be important to you as a practicing lawyer for a reason few students contemplate in law school. Once you begin
practice, you w ill find that the codified law — as it existed at the time you began
working in the field — is the baseline structure for your understanding of the way
that field works. Changes made by Congress a fter you begin practicing in a field
w ill, at least initially, seem like awkward additions to that initial baseline. And you
are likely to refer to them not as part of the FFDCA, but by the name of the individual statute that made the relevant statutory changes. (“This is mandated by the
21st Century Cures Act,” rather than “This is mandated by the FFDCA.”)
The same applies, of course, to the senior lawyers for whom you are likely to
work. U
 nless you are conversant with the names and general content of the individual statutes that have modified the FFDCA over time, you will not be able to
communicate effectively with your colleagues.
For regulatory provisions, the CFR is your best source of current law.9 Like with
statutes, it is necessary to turn to calendar-based materials — in this case, the

9. For most purposes, the best way to access the CFR is the eCFR (“Electronic Code of Federal
Regulations”) website maintained by the U.S. Government Publishing Office. It is free, usually
updated within a few days of any regulatory change, and — most importantly — formatted in a
manner that allows you to view an entire regulatory “Part” rather than just an individual “Section.”
In other words, it permits you to view all of 21 C.F.R. Part 101 — Food Labeling on a single page,
rather than requiring you to click individually on each subsection (21 C.F.R. §§ 101.1, 101.2, 101.15,
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Federal Register — to learn when a particu lar provision was added to, or removed
from, the CFR. But, for regulations, calendar-based materials play an additional
role. It is in these calendar-based materials — especially “Proposed Rules” and
“Final Rules” — that agencies today set out the reasoning behind their rulemaking
decisions.

The Relationship Between Food & Drug Regulation
and Administrative Law
Food & Drug Regulation is a course in a substantive regulatory field. In this
manner, it is similar to law school courses in Securities Regulation or Environmental Law. The general course in Administrative Law is not a course in a substantive
regulatory field. Instead, Administrative Law is a broad survey of the interactions
among executive branch agencies, Congress, and the courts.
This book is designed to present Food & Drug Regulation in a manner that is
accessible to students who have not yet taken Administrative Law. It is also designed
to avoid duplicating the coverage of an Administrative Law course.10 Past experience
suggests two things. First, students find that an earlier course in Food & Drug Regulation makes the abstract concepts of Administrative Law easier to understand.
Second, students find that an earlier course in Administrative Law gives them some
additional perspective on a later course in a Food & Drug Regulation. In other
words, whichever course you take first is likely to help you understand the course
you take later (or concurrently). And you w ill learn more by taking both courses
than by taking either course alone.

2. I ntroduction to This Chapter
This chapter introduces you to the history and structure of the U.S. Food and
Drug Administration (FDA). The first part of the chapter focuses on the agency’s
current structure and the historical context for the agency as it exists today. The
second part introduces a number of the product categories provided for in the Federal Food, Drug, and Cosmetic Act (FFDCA). It also introduces some of the difficulties involved in determining the category into which a particular product fits.

101.18, etc.). Unfortunately, t here does not seem to be a single web link that has remained stable
over time for the main eCFR landing page. Your best bet is to Google “eCFR gpo.gov” (including
“gpo.gov” is important, as “ecfr” alone sometimes turns up strange results).
10. The necessary exception is the Chevron case and the provisions of the Administrative Procedure Act discussed in the first part of Chapter 2 of this casebook. Chevron and the APA provisions
w ill have been covered in almost any Administrative Law course. But the remainder of Chapter 2,
on FDA’s administrative procedures, w ill be new material even to most alumni of a good Administrative Law course.
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Food and drug regulation is based around a limited set of product categories. All
of t hese are set out in just a few statutory and regulatory provisions: FFDCA § 201,
FFDCA § 503(g)(1), PHSA § 351, 21 C.F.R. §§ 3.2 and 1271.3(d).
FFDCA § 201 w
 ill provide you with the statutory definitions for most — but not
all — FDA-regulated product categories. You w
 ill want to bookmark that section, as
you w
 ill refer to it repeatedly throughout this course. PHSA § 351(i) w
 ill provide you
with the statutory definition of biological product (or biologic), which is not defined
in FFDCA § 201. FFDCA § 503(g)(1)(A), together with 21 C.F.R. § 3.2, w ill provide you with the definition of combination product. Finally, 21 C.F.R. § 1271.3(d)
w ill provide you with the regulatory definition of one product category that is not
defined explicitly by statute — human cells, tissues, and cellular and tissue-based
products (HCT/Ps).
At this point, please read (or review) the following excerpts in the statutory
supplement:
• FFDCA § 201. Definitions; generally.
• FFDCA § 503. Exemptions and considerations for certain drugs, devices, and
biological products. Subsection (g)(1) only. [statutory reference to combination
products]
• PHSA § 351. Regulations of biological products. Subsection (i) only.
• 21 C.F.R. § 3.2. [regulatory definition of “combination product”]
• 21 C.F.R. § 1271.3(d). [definition of “Human cells, tissues, and cellular or
tissue-based products” (HCT/Ps)]
Moving on from product categories, we turn to the core operational provision of
the statute: FFDCA § 301. The first three subsections, FFDCA § 301(a)–(c), set out
a general prohibition on adulteration and misbranding of FDA-regulated products.
Much of the remainder of the FFDCA simply describes actions that w ill make one
of t hese products adulterated or misbranded in violation of § 301. Other portions of
FFDCA § 301 prohibit other, more specific actions.
At this point, please read (or review) the following excerpts in the statutory
supplement:
• FFDCA § 301. Prohibited acts. Subsections (a), (b), and (c).
Finally, FFDCA § 1003(b) sets out FDA’s statutory mission statement. As you read
this, note that it has more significance than the mission statement developed internally by a private sector or public sector organization. Instead, this mission statement was prescribed in a major congressional effort to reform the agency, the FDA
Modernization Act of 1997. Subsection (f) — also part of that same 1997 statute — 
explicitly sets out Congress’s view that FDA was not then in compliance with its
statutory obligations. It directed the agency to develop a plan to bring itself into statutory compliance, and to report annually on its progress t oward such compliance.
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At this point, please read (or review) the following excerpts in the statutory
supplement:
• FFDCA § 1003. Food & Drug Administration. Subsections (b) and (f) only.

B. Outline of Regulatory Regime
This is your first example of the “Outline of Regulatory Regime” described in
the “Introduction to this Casebook” section, above. The first chart is a timeline of
key statutes, listed in chronological order. The second chart is a list of key statutory
provisions, listed in the order those provisions appear in the FFDCA and PHSA.
The third chart is a list of key regulatory provisions, listed in the order those appear
in the CFR. None of these charts is intended to be comprehensive, as comprehensive
charts would provide too much detail to be useful. Instead, they are intended to
give you a general sense of the statutory history, statutory structure, and regulatory
structure relevant to this casebook chapter.
As you read this chapter for the first time, you should do no more than skim these
charts to get a general sense of the structure of the applicable statutes and regulations.
As you begin to review the material at the end of the semester (or perhaps work on
a seminar paper), you may find it helpful to look back at these charts in more detail.
You should follow this same approach (skimming first, returning to read in more
detail later if necessary) in each “Outline of Regulatory Regimes” section of this book.
Timeline of Key Statutes: FDA Structure
Year

PL

Stat

Name of Statute

1906

59-384

34 Stat. 768

Pure Food and Drug Act

1938

75-717

52 Stat. 1040

FFDCA of 1938

1988

100-607 102 Stat. 3048, 3120

Food and Drug Administration Act of 1988

1997

105-115

FDA Modernization Act of 1997

111 Stat. 2296

Timeline of Key Statutes: Product Categories
Year

PL

Stat

Name of Statute

1906

59-384

34 Stat. 768

Pure Food and Drug Act

1938

75-717

52 Stat. 1040

FFDCA of 1938

1944

78-410

58 Stat. 682

Public Health Serv ices Act

1968

90-399

82 Stat. 342

Animal Drug Amendments of 1968

1976

94-295

90 Stat. 539

Medical Devices Amendments of 1976

1994

103-417 108 Stat. 4325

Dietary Supplement Health and Education Act of 1997

Copyright © 2021 Carolina Academic Press, LLC. All rights reserved.

1 · Agency Structure and Product Categories

Key Statutory Provisions: FDA Structure
Statute Name or U.S.C. Title

§

Title of Section or Subsection

FFDCA

1001

Separability clause

FFDCA

1003

Food and Drug Administration

FFDCA

1003a

Office of Pediatric Therapeutics

FFDCA

1004

Scientific review groups

FFDCA

1007

Contracts for expert review

FFDCA

1010

Office of the Chief Scientist

FFDCA

1011

Office of W
 omen’s Health

21 U.S.C.

399g

Food and Drug Administration Intercenter
Institutes

Key Statutory Provisions: Product Categories
Statute Name or U.S.C. Title

§

FFDCA

201

FFDCA

503(g)

FFDCA

563

Title of Section or Subsection
Definitions
Regulation of combination products
Classification of products

Key Statutory Provisions: Adulteration and Misbranding
Statute Name or U.S.C. Title

§

Title of Section or Subsection

FFDCA

201

Definitions

FFDCA

301

Prohibited acts

FFDCA

402, 501, Chapter-specific adulteration provisions
601, 902  402: food
 501: drugs, devices, biologics, combination
products
 601: cosmetics
 902: tobacco products

FFDCA

403, 502, Chapter-specific misbranding provisions
602, 903  403: food
 502: drugs, devices, biologics, combination
products
 602: cosmetics
 903: tobacco products

11
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Key Regulatory Provisions: FDA Structure
21 C.F.R.
Part
5

Subpart
— 

Title of Part or Subpart
Organization

Key Regulatory Provisions: Product Categories
21 C.F.R.
Part

Subpart

Title of Part or Subpart

3

— 

Product jurisdiction

1270

— 

Human tissue intended for transplantation

1271

— 

Human cells, tissues, and cellular and tissue-based products

C. Historical Context
1. O
 rganizational History
The excerpt immediately below, from FDA’s website, summarizes the orga
nizational history of FDA and its predecessor entities.

FDA Website, History of FDA’s Internal Organization:
Brief Organizational History*
In his 1837 annual report, Patent Commissioner Henry L. Ellsworth recommended a national agency for the encouragement of agriculture. Congress
responded in 1839 by an appropriation of $1000 to the Commissioner of Patents for
“the collection of agricultural statistics, and for other agricultural purposes.” From
then on, the Patent Office collected and reported agricultural statistics, sponsored
or conducted chemical investigations on agricultural m
 atters, monitored agricultural developments, and reported on all of these in its annual reports. Beginning
in 1849, a separate report was made by the Patent Commissioner to Congress on
agricultural matters. An Agricultural Division was established in the Patent Office
and a chemical laboratory was created in that Division.
When the U.S. Department of Agriculture was created in 1862, the Patent Office’s
Agricultural Division was transferred to the new Department, becoming the Division of Chemistry in 1890 and the Bureau of Chemistry in 1901. In 1927, the Bureau
of Chemistry became the United States Food, Drug and Insecticide Administration, and in 1930 the name was shortened to the U.S. Food and Drug Administration. Ten years later, in 1940, the FDA was transferred from the U.S. Department
of Agriculture to the newly created Federal Security Agency, which was renamed
* From https://w ww.f da.g ov/about-fda/history-fdas-fi
 ght-consumer-protection-a nd-public
-health/history-fdas-internal-organization (last updated January 31, 2018).
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the Department of Health Education and Welfare in 1953, and again renamed the
Department of Health and Human Serv ices in 1979.

2. F
 DA’s “Milestones” List
For some time now, FDA’s History Office has maintained a list of “Milestones in
U.S. Food and Drug Law History.” The most recent version at the time of this writing is excerpted below. Experience suggests that this is a useful document for t hose
seeking to learn food and drug regulation. You may find it helpful to bookmark this
list and refer to it later in the semester when you are trying to consolidate what you
have learned. Many of the milestones on this list w
 ill be more meaningful to you
after you have covered the relevant topics in more detail.

FDA Website, Milestones in U.S. Food and Drug Law History*
From the beginnings of civilization p
 eople have been concerned about the quality and safety of foods and medicines. In 1202, King John of E
 ngland proclaimed the
first English food law, the Assize of Bread, which prohibited adulteration of bread
with such ingredients as ground peas or beans. Regulation of food in the United
States dates from early colonial times. Federal controls over the drug supply began
with inspection of imported drugs in 1848, although the first federal biologics law,
which addressed the provision of reliable smallpox vaccine to citizens, was passed
in 1813. The following chronology describes some of the milestones in the history of
food and drug regulation in the United States.
1820
Eleven physicians meet in Washington, D.C., to establish the U.S. Pharmacopeia, the first compendium of standard drugs for the United States.
1848
Drug Importation Act passed by Congress requires U.S. Customs Serv ice
inspection to stop entry of adulterated drugs from overseas.
1862
President Lincoln appoints a chemist, Charles M. Wetherill, to serve in the
new Department of Agriculture. This was the beginning of the Bureau of
Chemistry, the predecessor of the Food and Drug Administration.
1880
Peter Collier, chief chemist, U.S. Department of Agriculture, recommends
passage of a national food and drug law, following his own food adulteration
investigations. The bill was defeated, but during the next 25 years more than
100 food and drug bills were introduced in Congress.

* From: https://w ww.fda.gov/about-fda/fdas-evolving-regulatory-powers/m
 ilestones-us-food
-a nd-drug-law-history (last updated January 31, 2018).
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1883
Dr. Harvey W. Wiley becomes chief chemist, expanding the Bureau of Chemistry’s food adulteration studies. Campaigning for a federal law, Dr. Wiley is
called the “Crusading Chemist” and “Father of the Pure Food and Drugs Act.”
He retired from government serv ice in 1912 and died in 1930.
1897
Tea Importation Act passed, providing for Customs inspection of all tea
entering U.S. ports, at the expense of the importers.
1898
Association of Official Agricultural Chemists (now AOAC International)
establishes a Committee on Food Standards headed by Dr. Wiley. States begin
incorporating these standards into their food statutes.
1902
The Biologics Control Act is passed to ensure purity and safety of serums,
vaccines, and similar products used to prevent or treat diseases in humans.
Congress appropriates $5,000 to the Bureau of Chemistry to study chemical
preservatives and colors and their effects on digestion and health. Dr. Wiley’s
studies draw widespread attention to the problem of food adulteration. Public
support for passage of a federal food and drug law grows.
1906
The original Food and Drugs Act is passed by Congress on June 30 and signed
by President Theodore Roosevelt. It prohibits interstate commerce in misbranded and adulterated foods, drinks and drugs.
The Meat Inspection Act is passed the same day.
Shocking disclosures of insanitary conditions in meat-packing plants, the use
of poisonous preservatives and dyes in foods, and cure-a ll claims for worthless and dangerous patent medicines w
 ere the major problems leading to the
enactment of these laws.
1907
First Certified Color Regulations, requested by manufacturers and users, list
seven colors found suitable for use in foods.
1911
In U.S. v. Johnson, the Supreme Court rules that the 1906 Food and Drugs
Act does not prohibit false therapeutic claims but only false and misleading
statements about the ingredients or identity of a drug.
1912
Congress enacts the Sherley Amendment to over come the ruling in U.S. v.
Johnson. It prohibits labeling medicines with false therapeutic claims intended
to defraud the purchaser, a standard difficult to prove.
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Mrs. Winslow’s Soothing Syrup for teething and colicky babies, unlabeled yet
laced with morphine, killed many infants.
1913
Gould Amendment requires that food package contents be “plainly and conspicuously marked on the outside of the package in terms of weight, measure,
or numerical count.”
1914
In U.S. v. Lexington Mill and Elevator Company, the Supreme Court issues
its first ruling on food additives. It ruled that in order for bleached flour with
nitrite residues to be banned from foods, the government must show a relationship between the chemical additive and the harm it allegedly caused in
humans. The court also noted that the mere presence of such an ingredient
was not sufficient to render the food illegal.
The Harrison Narcotic Act requires prescriptions for products exceeding the
allowable limit of narcotics and mandates increased record-keeping for physicians and pharmacists who dispense narcotics.
1924
In U.S. v. 95 Barrels Alleged Apple Cider Vinegar, the Supreme Court rules
that the Food and Drugs Act condemns e very statement, design, or device on
a product’s label that may mislead or deceive, even if technically true.
1927
The Bureau of Chemistry is reorganized into two separate entities. Regulatory
functions are located in the Food, Drug, and Insecticide Administration, and
nonregulatory research is located in the Bureau of Chemistry and Soils.
1930
McNary-Mapes Amendment authorizes FDA standards of quality and fill-of-
container for canned food, excluding meat and milk products.
The name of the Food, Drug, and Insecticide Administration is shortened to
Food and Drug Administration (FDA) under an agricultural appropriations
act.
1933
FDA recommends a complete revision of the obsolete 1906 Food and Drugs
Act. The first bill is introduced into the Senate, launching a five-year legislative battle.
1935
U.S. Government begins publication of the Federal Register.
1937
Elixir of Sulfanilamide, containing the poisonous solvent diethylene glycol, kills 107 persons, many of whom are c hildren, dramatizing the need to
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establish drug safety before marketing and to enact the pending food and
drug law.
1938
The Federal Food, Drug, and Cosmetic (FDC) Act of 1938 is passed by Congress, containing new provisions:
Extending control to cosmetics and therapeutic devices.
Requiring new drugs to be shown safe before marketing-starting a new system
of drug regulation.
Eliminating the Sherley Amendment requirement to prove intent to defraud
in drug misbranding cases.
Providing that safe tolerances be set for unavoidable poisonous substances.
Authorizing standards of identity, quality, and fill-of-container for foods.
Authorizing factory inspections.
Adding the remedy of court injunctions to the previous penalties of seizures
and prosecutions.
	Under the Wheeler-Lea Act, the Federal Trade Commission is charged with
overseeing advertising associated with products otherw ise regulated by FDA.
1939
First Food Standards issued (canned tomatoes, tomato purée, and tomato
paste).
1940
FDA transferred from the Department of Agriculture to the Federal Security Agency, with Walter G. Campbell appointed as the first Commissioner of
Food and Drugs.
1941
Insulin Amendment requires FDA to test and certify purity and potency of
this lifesaving drug for diabetes
1943
In U.S. v. Dotterweich, the Supreme Court rules that the responsible officials
of a corporation, as well as the corporation itself, may be prosecuted for violations. It need not be proven that the officials intended, or even knew of, the
violations.
1944
Public Health Service Act is passed, covering a broad spectrum of health concerns, including regulation of biological products and control of communicable diseases.
1945
Penicillin Amendment requires FDA testing and certification of safety and
effectiveness of all penicillin products. 
Later amendments extended this
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requirement to all antibiotics. In 1983 such control was found no longer
needed and was abolished.
1948
Miller Amendment affirms that the [FFDCA] applies to goods regulated by
the Agency that have been transported from one state to another and have
reached the consumer.
1949
FDA publishes guidance to industry for the first time. This guidance, “Procedures for the Appraisal of the Toxicity of Chemicals in Food,” came to be
known as the “black book.”
1950
In Alberty Food Products Co. v. U.S., a court of appeals rules that the directions for use on a drug label must include the purpose for which the drug is
offered. Therefore, a worthless remedy cannot escape the law by not stating
the condition it is supposed to treat.
Oleomargarine Act requires prominent labeling of colored oleomargarine, to
distinguish it from butter.
Delaney Committee starts congressional investigation of the safety of chemicals in foods and cosmetics, laying the foundation for the 1954 Miller Pesticide Amendment, the 1958 Food Additives Amendment, and the 1960 Color
Additive Amendment.
1951
Durham-Humphrey Amendment defines the kinds of drugs that cannot be
safely used without medical supervision and restricts their sale to prescription
by a licensed practitioner.
1952
In U.S. v. Cardiff, the Supreme Court rules that the factory inspection provision of the 1938 FDC Act is too vague to be enforced as criminal law.
FDA consumer consultants are appointed in each field district to maintain
communications with consumers and ensure that FDA considers their needs
and problems.
1953
Federal Security Agency becomes the Department of Health, Education, and
Welfare (HEW).
Factory Inspection Amendment clarifies previous law and requires FDA to
give manufacturers written reports of conditions observed during inspections
and analyses of factory samples.
1954
Miller Pesticide Amendment spells out procedures for setting safety limits for
pesticide residues on raw agricultural commodities.
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First large-scale radiological examination of food carried out by FDA when it
received reports that tuna suspected of being radioactive was being imported
from Japan following atomic blasts in the Pacific. FDA begins monitoring
around the clock to meet the emergency.
1955
HEW Secretary Oveta Culp Hobby appoints a committee of 14 citizens to
study the adequacy of FDA’s facilities and programs. The committee recommends a substantial expansion of FDA staff and facilities, a new headquarters
building, and more use of educational and informational programs.
The Division of Biologics Control became an independent entity within the
National Institutes of Health, a fter polio vaccine thought to have been inactivated is associated with about 260 cases of polio.
1958
Food Additives Amendment enacted, requiring manufacturers of new food
additives to establish safety. The Delaney proviso prohibits the approval of
any food additive shown to induce cancer in humans or animals.
FDA publishes in the Federal Register the first list of substances generally recognized as safe (GRAS). The list contains nearly 200 substances.
1959
U.S. cranberry crop recalled three weeks before Thanksgiving for FDA tests
to check for aminotriazole, a weedkiller found to cause cancer in laboratory
animals. Cleared berries w
 ere allowed a label stating that they had been tested
and had passed FDA inspection, the only such endorsement ever allowed by
FDA on a food product.
1960
Color Additive Amendment enacted, requiring manufacturers to establish
the safety of color additives in foods, drugs and cosmetics. The Delaney proviso prohibits the approval of any color additive shown to induce cancer in
humans or animals.
Federal Hazardous Substances Labeling Act, enforced by FDA, requires
prominent label warnings on hazardous household chemical products.
1962
Thalidomide, a new sleeping pill, is found to have caused birth defects in
thousands of babies born in western Europe. News reports on the role of
Dr. Frances Kelsey, FDA medical officer, in keeping the drug off the U.S. market, arouse public support for stronger drug regulation.
Kefauver-Harris Drug Amendments passed to ensure drug efficacy and
greater drug safety. For the first time, drug manufacturers are required to
prove to FDA the effectiveness of their products before marketing them. The
new law also exempts from the Delaney proviso animal drugs and animal

Copyright © 2021 Carolina Academic Press, LLC. All rights reserved.

1 · Agency Structure and Product Categories

19

feed additives shown to induce cancer but which leave no detectable levels of
residue in the human food supply.
Consumer Bill of Rights is proclaimed by President John F. Kennedy in a
message to Congress. Included are the right to safety, the right to be informed,
the right to choose, and the right to be heard.
1965
Drug Abuse Control Amendments are enacted to deal with problems caused
by abuse of depressants, stimulants and hallucinogens.
1966
FDA contracts with the National Academy of Sciences/National Research
Council to evaluate the effectiveness of 4,000 drugs approved on the basis of
safety alone between 1938 and 1962.
Child Protection Act enlarges the scope of the Federal Hazardous Substances
Labeling Act to ban hazardous toys and other articles so hazardous that adequate label warnings could not be written.
Fair Packaging and Labeling Act requires all consumer products in interstate
commerce to be honestly and informatively labeled, with FDA enforcing provisions on foods, drugs, cosmetics, and medical devices.
1968
FDA Bureau of Drug Abuse Control and Treasury Department Bureau of
Narcotics are transferred to the Department of Justice to form the Bureau of
Narcotics and Dangerous Drugs (BNDD), consolidating efforts to police traffic in abused drugs.
Reorganization of federal health programs places FDA in the Public Health
Serv ice.
FDA forms the Drug Efficacy Study Implementation (DESI) to implement
recommendations of the National Academy of Sciences investigation of effectiveness of drugs first marketed between 1938 and 1962.
Animal Drug Amendments place all regulation of new animal drugs u
 nder
one section of the Food, Drug, and Cosmetic Act — Section 512 — making
approval of animal drugs and medicated feeds more efficient.
1969
FDA begins administering Sanitation Programs for milk, shellfish, food ser
vice, and interstate travel facilities, and for preventing poisoning and accidents. T
 hese responsibilities w
 ere transferred from other units of the Public
Health Serv ice.
The White House Conference on Food, Nutrition, and Health recommends
systematic review of GRAS substances in light of FDA’s ban of the artificial
sweetener cyclamate. President Nixon o
 rders FDA to review its GRAS list.
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1970
In Upjohn v. Finch the Court of Appeals upholds enforcement of the 1962
drug effectiveness amendments by ruling that commercial success alone does
not constitute substantial evidence of drug safety and efficacy.
FDA requires the first patient package insert: oral contraceptives must contain information for the patient about specific risks and benefits.
Drug Abuse Prevention and Control Act replaces previous laws and categorizes drugs based on abuse and addiction potential compared to their therapeutic value.
Environmental Protection Agency established; takes over FDA program for
setting pesticide tolerances.
1971
PHS Bureau of Radiological Health transferred to FDA. Its mission: protection against unnecessary h
 uman exposure to radiation from electronic products in the home, industry, and the healing arts.
National Center for Toxicological Research is established in the biological facilities of the Pine Bluff Arsenal in Arkansas. Its mission is to examine
biological effects of chemicals in the environment, extrapolating data from
experimental animals to h
 uman health.
Artificial sweetener saccharin, included in FDA’s original GRAS list, is
removed from the list pending new scientific study.
1972
Over-the-Counter Drug Review begun to enhance the safety, effectiveness
and appropriate labeling of drugs sold without prescription.
Regulation of Biologics — including serums, vaccines, and blood products — 
is transferred from NIH to FDA.
1973
The U.S. Supreme Court upholds the 1962 drug effectiveness law and endorses
FDA action to control entire classes of products by regulations rather than to
rely only on time-consuming litigation.
Low-acid food processing regulations issued, a fter botulism outbreaks from
canned foods, to ensure that low-acid packaged foods have adequate heat
treatment and are not hazardous.
Consumer Product Safety Commission created by Congress; takes over programs pioneered by FDA u
 nder 1927 Caustic Poison Act, 1960 Federal Hazardous Substances Labeling Act, 1966 Child Protection Act, and PHS accident
prevention activities for safety of toys, home appliances, etc.
1976
Medical Device Amendments passed to ensure safety and effectiveness of
medical devices, including diagnostic products. The amendments require
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manufacturers to register with FDA and follow quality control procedures.
Some products must have pre-market approval by FDA; o
 thers must meet
performance standards before marketing.
Vitamins and Minerals Amendments (“Proxmire Amendments”) stop FDA
from establishing standards limiting potency of vitamins and minerals in
food supplements or regulating them as drugs based solely on potency.
1977
Saccharin Study and Labeling Act passed by Congress to stop FDA from banning the chemical sweetener but requiring a label warning that it has been
found to cause cancer in laboratory animals.
1979
Introduction of the Bioresearch Monitoring Program as an agency-w ide initiative ensures the quality and integrity of data submitted to FDA and provides for the protection of human subjects in clinical trials by focusing on
preclinical studies on animals, clinical investigations, and the work of institutional review boards.
In the hours following the Three Mile Island nuclear emergency of March 28,
1979, FDA contracted with firms in Missouri, Michigan, and New Jersey
to prepare and package enough doses of potassium iodide to protect those
threatened with thyroid cancer if exposed to radiation. Nearly one quarter of
a million bottles — enough for every household in the area — were delivered
to Harrisburg, Pennsylvania within 72 hours.
1980
Infant Formula Act establishes special FDA controls to ensure necessary
nutritional content and safety
1981
FDA and the Department of Health and Human Serv ices revise regulations
for human subject protections, based on the 1979 Belmont Report, which had
been issued by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The revised rules provide for
wider representation on institutional review boards and they detail elements
of what constitutes informed consent, among other provisions.
1982
Tamper-resistant Packing Regulations issued by FDA to prevent poisonings
such as deaths from cyanide placed in Tylenol capsules. The Federal Anti-
Tampering Act passed in 1983 makes it a crime to tamper with packaged consumer products.
FDA publishes first Red Book (successor to 1949 “black book”), officially
known as Toxicological Principles for the Safety Assessment of Direct Food
Additives and Color Additives Used in Food.
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1983
Orphan Drug Act passed, enabling FDA to promote research and marketing
of drugs needed for treating rare diseases.
1984
Fines Enhancement Laws of 1984 and 1987 amend the U.S. Code to greatly
increase penalties for all federal offenses. The maximum fine for individuals
is now $100,000 for each offense and $250,000 if the violation is a felony or
causes death. For corporations, the amounts are doubled.
Drug Price Competition and Patent Term Restoration Act expedites the
availability of less costly generic drugs by permitting FDA to approve applications to market generic versions of brand-name drugs without repeating the
research done to prove them safe and effective. At the same time, the brand-
name companies can apply for up to five years additional patent protection
for the new medicines they developed to make up for time lost while their
products were g oing through FDA’s approval process.
1985
AIDS test for blood approved by FDA in its first major action to protect
patients from infected donors.
1986
Childhood Vaccine Act requires patient information on vaccines, gives FDA
authority to recall biologics, and authorizes civil penalties.
1987
Investigational drug regulations revised to expand access to experimental
drugs for patients with serious diseases with no alternative therapies.
1988
Food and Drug Administration Act of 1988 officially establishes FDA as an
agency of the Department of Health and Human Serv ices with a Commissioner of Food and Drugs appointed by the President with the advice and consent of the Senate, and broadly spells out the responsibilities of the Secretary
and the Commissioner for research, enforcement, education, and information.
The Prescription Drug Marketing Act bans the diversion of prescription
drugs from legitimate commercial channels. Congress finds that the resale
of such drugs leads to the distribution of mislabeled, adulterated, subpotent,
and counterfeit drugs to the public. The new law requires drug w
 holesalers
to be licensed by the states; restricts reimportation from other countries; and
bans sale, trade or purchase of drug samples, and traffic or counterfeiting of
redeemable drug coupons.
Generic Animal Drug and Patent Term Restoration Act extends to veterinary products benefits given to h
 uman drugs u
 nder the 1984 Drug Price
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Competition and Patent Term Restoration Act. Companies can produce
and sell generic versions of animal drugs approved a fter October 1962 without duplicating research done to prove them safe and effective. The act also
authorizes extension of animal drug patents.
1989
FDA issues a nationwide recall of all over-the-counter dietary supplements
containing 100 milligrams or more of L-Tryptophan, due to a clear link
between the consumption of L-tryptophan tablets and its association with
a U.S. outbreak of Eosinophilia Myalgia Syndrome (EMS), characterized by
fatigue, shortness of breath, and other symptoms. By 1990 the Centers for Disease Control and Prevention confirm over 1,500 cases of EMS, including 38
deaths, and FDA prohibits the importation of l-tryptophan.
1990
Responding to increasing illicit traffic, Congress passes the Anabolic Steroid
Act of 1990, which identifies anabolic steroids as a class of drugs and specifies over two dozen items as controlled substances. In addition, a four-part
definition of this class is established to permit new, black market compounds
to be assigned to this category, and thus subject to regulation as controlled
substances.
Nutrition Labeling and Education Act requires all packaged foods to bear
nutrition labeling and all health claims for foods to be consistent with terms
defined by the Secretary of Health and Human Serv ices. The law preempts
state requirements about food standards, nutrition labeling, and health
claims and, for the first time, authorizes some health claims for foods. The
food ingredient panel, serving sizes, and terms such as “low fat” and “light”
are standardized.
Safe Medical Devices Act is passed, requiring nursing homes, hospitals, and
other facilities that use medical devices to report to FDA incidents that suggest that a medical device probably caused or contributed to the death, serious
illness, or serious injury of a patient. Manufacturers are required to conduct
post-market surveillance on permanently implanted devices whose failure
might cause serious harm or death, and to establish methods for tracing and
locating patients depending on such devices. The act authorizes FDA to order
device product recalls and other actions.
1991
Regulations published to Accelerate the Review of Drugs for life-threatening
diseases.
The policy for protection of human subjects in research, promulgated in 1981
by FDA and the Department of Health and Human Serv ices, is adopted by
more than a dozen federal entities involved in h
 uman subject research and
becomes known as the Common Rule. This rule issues requirements for

Copyright © 2021 Carolina Academic Press, LLC. All rights reserved.

24

1 · Agency Structure and Product Categories

researchers who obtain and document informed consent, secures special protection for c hildren, women, and prisoners, elaborates on required procedures
for institutional review boards, and ensures that research institutions comply
with the regulations.
1992
Generic Drug Enforcement Act imposes debarment and other penalties for
illegal acts involving abbreviated drug applications.
Prescription Drug User Fee Act requires drug and biologics manufacturers to pay fees for product applications and supplements, and other serv ices.
The act also requires FDA to use t hese funds to hire more reviewers to assess
applications.
Mammography Quality Standards Act requires all mammography facilities
in the United States to be accredited and federally certified as meeting quality
standards effective Oct. 1, 1994. After initial certification, facilities must pass
annual inspections by federal or state inspectors.
Nutrition facts, basic per-serving nutritional information, are required on
foods u
 nder the Nutrition Labeling and Education Act of 1990. Based on the
latest public health recommendations, FDA and the Food Safety and Inspection Serv ice of the Department of Agriculture recreate the food label to list the
most important nutrients in an easy-to-follow format.
1993
A consolidation of several adverse reaction reporting systems is launched as
MedWatch, designed for voluntary reporting of problems associated with
medical products to be filed with FDA by health professionals.
Revising a policy from 1977 that excluded women of childbearing potential
from early drug studies, FDA issues guidelines calling for improved assessments of medication responses as a function of gender. Companies are
encouraged to include patients of both sexes in their investigations of drugs
and to analyze any gender-specific phenomena.
1994
Dietary Supplement Health and Education Act establishes specific labeling
requirements, provides a regulatory framework, and authorizes FDA to promulgate good manufacturing practice regulations for dietary supplements.
This act defines “dietary supplements” and “dietary ingredients” and classifies them as food. The act also establishes a commission to recommend how to
regulate claims.
FDA announces it could consider regulating nicotine in cigarettes as a drug,
in response to a Citizen’s Petition by the Coa lition on Smoking OR Health.
Uruguay Round Agreements Act extends the patent terms of U.S. drugs from
17 to 20 years.
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Animal Medicinal Drug Use Clarification Act allows veterinarians to prescribe extra-label use of veterinary drugs for animals u
 nder specific circumstances. In addition, the legislation allows licensed veterinarians to prescribe
human drugs for use in animals under certain conditions.
1995
FDA declares cigarettes to be “drug delivery devices.” Restrictions are proposed on marketing and sales to reduce smoking by young people.
A series of proposed reforms to reduce regulatory burden on pharmaceuti
cal manufacturers is announced, including an expansion of allowable promotional material on approved uses of drugs that firms can distribute to health
professionals, streamlining certain elements in the documentation of investigational drug studies, and a reduction in both environmental impact filings
and pre-approval requirements in tablet manufacture.
1996
Federal Tea Tasters Repeal Act repeals the Tea Importation Act of 1897
to eliminate the Board of Tea Experts and user fees for FDA’s testing of all
imported tea. Tea itself is still regulated by FDA.
Saccharin Notice Repeal Act repeals the saccharin notice requirements.
Animal Drug Availability Act adds flexibility to animal drug approval pro
cess, providing for flexible labeling and more direct communication between
drug sponsors and FDA.
Food Quality Protection Act amends the Food, Drug, and Cosmetic Act,
eliminating application of the Delaney proviso to pesticides.
1997
Food and Drug Administration Modernization Act reauthorizes the Prescription Drug User Fee Act of 1992 and mandates the most wide-ranging
reforms in agency practices since 1938. Provisions include measures to accelerate review of devices, regulate advertising of unapproved uses of approved
drugs and devices, and regulate health claims for foods.
1998
FDA promulgates the Pediatric Rule, a regulation that requires manufacturers
of selected new and extant drug and biological products to conduct studies to
assess their safety and efficacy in c hildren.
Mammography Quality Standards Reauthorization Act continues 1992 Act
u
 ntil 2002.
First phase to consolidate FDA laboratories nationwide from 19 facilities to 9
by 2014 includes dedication of the first of five new regional laboratories.
1999
ClinicalTrials.gov is founded to provide the public with updated information
on enrollment in federally and privately supported clinical research, thereby
expanding patient access to studies of promising therapies.
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A final rule mandates that all over-the-counter drug labels must contain data
in a standardized format. These drug facts are designed to provide the patient
with easy-to-find information, analogous to the nutrition facts label for foods.
2000
The U. S. Supreme Court, upholding an e arlier decision in Food and Drug
Administration v. Brown & Williamson Tobacco Corp. et al., ruled 5–4 that
FDA does not have authority to regulate tobacco as a drug. Within weeks
of this ruling, FDA revokes its final rule, issued in 1996, that restricted the
sale and distribution of cigarettes and smokeless tobacco products to children
and adolescents, and that determined that cigarettes and smokeless tobacco
products are combination products consisting of a drug (nicotine) and device
components intended to deliver nicotine to the body.
Federal agencies are required to issue guidelines to maximize the quality,
objectivity, utility, and integrity of the information they generate, and to provide a mechanism whereby t hose affected can secure correction of information that does not meet these guidelines, u
 nder the Data Quality Act.
Publication of a rule on dietary supplements defines the type of statement
that can be labeled regarding the effect of supplements on the structure or
function of the body.
2002
The Best Pharmaceuticals for C
 hildren Act improves safety and efficacy of
patented and off-patent medicines for children. It continues the exclusivity
provisions for pediatric drugs as mandated under the Food and Drug Administration Modernization Act of 1997, in which market exclusivity of a drug is
extended by six months, and in exchange the manufacturer carries out studies of the effects of drugs when taken by children. The provisions both clarify aspects of the exclusivity period and amend procedures for generic drug
approval in cases when pediatric guidelines are added to the labeling.

	

In the wake of the events of September 11, 2001, the Public Health Security
and Bioterrorism Preparedness and Response Act of 2002 is designed to
improve the country’s ability to prevent and respond to public health emergencies, and provisions include a requirement that FDA issue regulations to
enhance controls over imported and domestically produced commodities it
regulates.
Under the Medical Device User Fee and Modernization Act, fees are assessed
sponsors of medical device applications for evaluation, provisions are established for device establishment inspections by accredited third-parties, and
new requirements emerge for reprocessed single-use devices.
The Office of Combination Products is formed within the Office of the Commissioner, as mandated under the Medical Device User Fee and Modernization Act, to oversee review of products that fall into multiple jurisdictions
within FDA.
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An effort to enhance and update the regulation of manufacturing processes
and end-product quality of animal and h
 uman drugs and biological medicines is announced, the current good manufacturing practice (cGMP) initiative. The goals of the initiative are to focus on the greatest risks to public
health in manufacturing procedures, to ensure that process and product quality standards do not impede innovation, and to apply a consistent approach to
these issues across FDA.
2003
The Medicare Prescription Drug Improvement and Modernization Act
requires, among other elements, that a study be made of how current and
emerging technologies can be utilized to make essential information about
prescription drugs available to the blind and visually impaired.
To help consumers choose heart-healthy foods, the Department of Health and
Human Serv ices announces that FDA w ill require food labels to include trans
fat content, the first substantive change to the nutrition facts panel on foods
since the label was changed in 1993.
An obesity working group is established by the Commissioner of Food and
Drugs, charged to develop an action plan to deal with the nation’s obesity epidemic from the perspective of FDA. In March 2004 the group releases “Calories Count: Report of the Obesity Working Group,” which addresses issues
connected to the food label, obesity therapeutics, research needs, the role of
education, and other topics.
The National Academy of Sciences releases “Scientific Criteria to Ensure Safe
Food,” a report commissioned by FDA and the Department of Agriculture,
which buttresses the value of the Hazard Analysis and Critical Control Point
(HACCP) approach to food safety already in place at FDA and invokes the
need for continued efforts to make food safety a vital part of our overall public health mission.
The Animal Drug User Fee Act permits FDA to collect subsidies for the review
of certain animal drug applications from sponsors, analogous to laws passed
for the evaluation of other products FDA regulates, ensuring the safety and
effectiveness of drugs for animals and the safety of animals used as foodstuffs.
FDA is given clear authority under the Pediatric Research Equity Act to
require that sponsors conduct clinical research into pediatric applications for
new drugs and biological products.
2004
Project BioShield Act of 2004 authorizes FDA to expedite its review procedures to enable rapid distribution of treatments as countermeasures to chemical, biological, and nuclear agents that may be used in a terrorist attack against
the U. S., among other provisions.
Passage of the Food Allergy Labeling and Consumer Protection Act requires
the labeling of any food that contains a protein derived from any one of the
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following foods that, as a group, account for the vast majority of food allergies: peanuts, soybeans, cow’s milk, eggs, fish, crustacean shellfish, tree nuts,
and wheat.
A ban on over-the-counter steroid precursors, increased penalties for making,
selling, or possessing illegal steroids precursors, and funds for preventive education to children are features of the Anabolic Steroid Control Act of 2004.
FDA publishes “Innovation or Stagnation? — Challenge and Opportunity on
the Critical Path to New Medical Products,” which examines the critical path
needed to bring therapeutic products to fruition, and how FDA can collaborate in the process, from laboratory to production to end use, to make medical
breakthroughs available to those in need as quickly as possible.
Based on recent results from controlled clinical studies indicating that Cox-2
selective agents may be connected to an elevated risk of serious cardiovascular
events, including heart attack and stroke, FDA issues a public health advisory
urging health professionals to limit the use of t hese drugs.
To provide for the treatment of animal species other than cattle, horses, swine,
chickens, turkeys, dogs, and cats, as well as other species that may be added at
a later time, the Minor Use and Minor Species Animal Health Act is passed
to encourage the development of treatments for species that would otherw ise
attract l ittle interest in the development of veterinary therapies.
Deeming such products to present an unreasonable risk of harm, FDA bans
dietary supplements containing ephedrine alkaloids based on an increasing
number of adverse events linked to these products and the known pharmacology of these alkaloids.
2005
Formation of the Drug Safety Board is announced, consisting of FDA staff
and representatives from the National Institutes of Health and the Veterans
Administration. The Board w ill advise the Director, Center for Drug Evaluation and Research, FDA, on drug safety issues and work with the agency in
communicating safety information to health professionals and patients.
2009
President Obama signs the Family Smoking Prevention and Tobacco Control
Act into law. The Tobacco Control Act gives FDA authority to regulate the
manufacture, distribution, and marketing of tobacco products to protect public health.
FDA Center for Tobacco Products established.
FDA announced a ban on cigarettes with flavors characterizing fruit, candy,
or clove.
2011
FDA Food Safety and Modernization Act (FSMA). FSMA provides FDA with
new enforcement authorities related to food safety standards, gives FDA tools
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to hold imported foods to the same standards as domestic foods, and directs
FDA to build an integrated national food safety system in partnership with
state and local authorities.
2012
Food and Drug Administration Safety and Innovation Act (FDASIA).
Expands FDA authorities to collect user fees from industry to fund reviews
of innovator drugs, medical devices, generic drugs and biosimilar biological
products; promotes innovation to speed patient access to safe and effective
products; increases stakeholder involvement in FDA processes, and enhances
the safety of the drug supply chain.
Medical Device User Fee and Modernization Act (MDUFMA III). As part
of FDASIA, reauthorizes user fees from industry to fund reviews of medical
devices in exchange for FDA to meet certain performance goals.
In 2012, an outbreak of fungal meningitis linked to a contaminated compounded drug product resulted in the loss of 64 lives and caused more than
751 illnesses. In response, Congress enacted the 2013 Drug Quality and Security Act (DQSA) that insures greater regulatory oversight of facilities creating
compounded drugs.
2013
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Establishes and reauthorizes certain programs u
 nder the Public Health Ser
vice Act and the Food, Drug, and Cosmetic Act with respect to public health
security and all-hazards preparedness and response.
Drug Quality and Security Act. Following an outbreak in 2012 of an epidemic
of fungal meningitis linked to a compounded steroid, Congress enacted the
Drug Quality Safety and Security Act (DQSA). Among other provisions it
outlines steps for an electronic and interoperable system to identify and trace
certain prescription drugs throughout the U.S.
[FDA’s milestones list ends in 2013.]

D. Product Categories
The entire structure of food and drug regulation is based on the idea of product
categories. To know the regulatory requirements that apply to a particular product,
you must first know the category into which it falls.
Most categories are initially defined by Congress at the statutory level. These are
found in the U.S. Code. Except for the provisions governing biologics, these are
found in FFDCA § 201. The provisions governing biologics are found in § 351(i) of
PHSA. One category, today known as HCT/Ps, is defined only by regulation, based
on authority granted in § 361 of the PHSA. Another category, combination products,
is referenced in FFDCA § 503(g)(1) and defined by regulation in 21 C.F.R. § 3.2.
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Further definition of the product categories is done by FDA at the regulatory
level. These are found in the Code of Federal Regulations. They are not consolidated
in a few areas, as the statutory definitions are. Instead, they tend to be intermixed
with the other provisions relating to the relevant product category.

1. C
 ategorization Problems
New products do not always fit easily into existing product categories. Sometimes a new product is genuinely outside existing categories. Other times, a product
potentially fits into two or more categories, but would be subject to heavier regulation in one category than the other.
One of the historically significant product-category disputes reached the U.S.
Supreme Court in United States v. An Article of Drug . . . Bacto-Unidisk (1969).
This case was a dispute over whether a particular product, an antibiotic sensitivity
disk, should be regulated as a drug or a medical device. U
 nder then-existing law,
drugs w
 ere subject to marketing authorization for both safety and efficacy. Medical
devices, by contrast, did not have to undergo any marketing authorization. (This
would begin to change seven years later, with the passage of the Medical Device
Amendments of 1976).
As you read, think about the problems associated with regulating industries
where major innovations often involve previously nonexistent technology. We w ill
return to Bacto-Unidisk when we discuss both drug and medical device regulation.
 ill find several references to FFDCA § 507.
Note: In the Bacto-Unidisk case, you w
This provision, specific to antibiotic drugs, was repealed by the Food and Drug Administration Modernization Act of 1997. Today, new antibiotic drugs are regulated, like
other new drugs, u
 nder FFDCA § 505.

United States v. An Article of Drug . . . Bacto-Unidisk . . .
394 U.S. 784 (1969)
Mr. Chief Justice WARREN delivered the opinion of the court.
At issue h
 ere is the scope of the statutory definition of drug contained in the
[FFDCA] and the extent of the Secretary of Health, Education, and Welfare’s regulatory authority under that definition. The specific item involved in this definitional
controversy is a laboratory aid known as an antibiotic sensitivity disc, used as a screening test for help in determining the proper antibiotic drug to administer to patients.
If the article is a “drug” within the general definition of § 201 of the [FFDCA], then
the Secretary can subject it to pre-market clearance regulations promulgated pursuant to § 507 of the [FFDCA]. Section 507 authorizes the Secretary to require batch
certification of any antibiotic product which also meets the general drug definition
of § 201. If, on the other hand, the article is merely a “device” under the [FFDCA],
it is subject only to the misbranding and adulteration proscriptions of the [FFDCA]
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and does not have to be pre-tested before marketing; and, of course, if the disc does
not fall u
 nder e ither definition, the [FFDCA] itself is totally inapplicable.
When the discs w
 ere marketed without complying with the certification regulations of the Secretary, the Government condemned them pursuant to § 334 of
the [FFDCA] on the assumption that the discs were drugs and thus validly subject to pre-market regulation. In this action following the condemnation, however,
the United States District Court for the Eastern District of Michigan held that the
discs were not drugs within the meaning of the [FFDCA], suggesting that, if any-
thing, they were devices. It therefore ruled that, since pre-market clearance was not
required or authorized, the seizure was improper. The Court of Appeals for the
Sixth Circuit affirmed on the same reasoning. We reverse.
I.
Some background information about the development of the discs and the controlling legislation is necessary for an understanding of the determinations made by
the Secretary and the courts below. Various antibiotics, known more commonly as
“wonder drugs” . . . have proved very useful since World War II in treating numerous infectious diseases. Produced biologically, however, these drugs tend to vary
greatly in their quality and potency u
 nless developed, and thereafter tested, under
very carefully controlled conditions. Consequently, Congress enacted § 507 of the
Food, Drug, and Cosmetic Act, directing the Secretary of Health, Education, and
Welfare to promulgate regulations establishing such standards of identity, potency,
quality, and purity as necessary to ensure the “safety” and “efficacy” of those
antibiotics. . . .
With the proliferation of the various types of antibiotics, doctors found a need
for a screening test to help choose which antibiotic to use in treating a particular
infection. . . . In this test, a round paper disc, which has been impregnated with a
specific antibiotic, is placed in contact with sample cultures, or isolates, of a patient’s
virus, grown in a special culture medium (agar) from a specimen of the patient’s
fluid (blood, spinal fluid, sputum, urine, e tc.). In t hose places impregnated with an
antibiotic to which the patient’s infection is sensitive, no new isolate w ill grow, leaving a clear area (an “inhibition zone”); in those places impregnated with a drug to
which the infection is resistant, the isolate w
 ill grow, leaving no clear area. . . .
 fter notice and an opportunity for public participation, the Commissioner of
A
Food and Drugs, under authority delegated by the Secretary, promulgated regulations requiring pre-clearance, batch-testing, and certification of antibiotic sensitivity discs. The Commissioner’s action, the regulations noted, followed “numerous
complaints by the medical profession, hospitals, and laboratory technicians” and a
resulting extensive survey of the use of the discs. That study found the discs unreliable in their statements of potency with resulting loss of safety and efficacy, and
thus found it “vital for the protection of the public health” to adopt the regulations.
This case arose in May 1962 as an in rem seizure proceeding against an interstate shipment of a number of cases of sensitivity discs, manufactured by Difco
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Laboratories, Inc., under the trade name of “Bacto-Unidisk.” In condemning the
product pursuant to § 301 et seq. of the Food, Drug, and Cosmetic Act, the United
States claimed, inter alia, that the product, as a “drug” within the meaning of the
[FFDCA], had not been certified nor exempted from certification as required by
§ 507 and the regulations thereunder and was therefore misbranded under § 502. . . . 
Since the scope of the Secretary’s pre-market regulatory power over antibiotic drugs
under § 507 depends ultimately on the [FFDCA]’s general definition of “drug” in
§ 201(g), the validity of the disc regulations allegedly v iolated turned on the coverage of the drug definition:
For the purposes of this chapter — 
....
(g)(1) The term ‘drug’ means (A) articles recognized in the official
United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of
the United States, or official National Formulary, or any supplement to
any of them; and (B) articles intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in man or other animals;
and (C) articles (other than food) intended to affect the structure or any
function of the body of man or other animals; and (D) articles intended
for use as a component of any article specified in clauses (A), (B), or
(C) of this paragraph; but does not include devices or their components,
parts, or accessories.
If, on the other hand, the product was a “device,” only the misbranding, adulteration, and labeling provisions of §§ 501 and 502 applied, and the Secretary’s disc
certification regulations w
 ere invalidly promulgated. Although a “device” expressly
cannot be a “drug” u
 nder the last phrase of the drug definition above, a device is
given almost a parallel definition in § 201(h):
The term ‘device’ . . . means instruments, apparatus, and contrivances,
including their components, parts, and accessories, intended (1) for use in
the diagnosis, cure, mitigation, treatment, or prevention of disease in man
or other animals; or (2) to affect the structure or any function of the body
of man or other animals.
Finally, it was established at trial that of the various definitions given above, the
operative ones in this case w
 ere § 201(g)(1)(B) of the drug provision and § 201(h)(1)
of the parallel device definition; the essential question underlying the validity of the
regulations, then, was w
 hether the Bacto-Unidisks w
 ere “articles intended for use in
the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other
animals.”
. . . . The District Court pointed out that although a “literal reading” of § 201(g)
(1)(B) “clearly has application to the article libeled herein,” enforcing such an application would be “ridiculous and contrary to common sense.” The court therefore
held that the Bacto-Unidisk did not fall within the purview of the [FFDCA] for the
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reason that it was not medically a drug, and suggested, without deciding, that the
discs would be more appropriately classified as “devices” under the [FFDCA].
On appeal, the Court of Appeals for the Sixth Circuit affirmed, accepting the
District Court’s conclusions that the Bacto-Unidisk was not a “drug” in the medical sense of the term and that Congress did not intend the statutory definition of
“drug” to be any broader than the medical one. . . . We granted the Government’s
petition for certiorari because this interpretation of the [FFDCA] raised issues of
importance in the administration of the [FFDCA].
II.
. . . . The courts below quite properly confined the inquiry to an examination
of w
 hether the disc regulations, even if medically unwise, w
 ere authorized by the
[FFDCA], and more specifically, by the [FFDCA]’s definition of “drug.” . . . Our
sole concern is w
 hether the statute’s definition of “drug” authorizes the disc regulations contested here; and while we agree with the lower courts’ limited conception
of the issue, for reasons outlined below, we reverse their disposition of it.
Respondent’s primary contention here is that the sensitivity discs are not subject to any of the provisions of the [FFDCA] b
 ecause Congress did not intend it to
cover articles used so indirectly in the “cure, mitigation, [and] treatment” of disease. Respondent uses the same two-step analysis relied on by the courts below: (1)
Congress did not intend to write the drug definition more broadly than does the
medical profession, and (2) the medical concept of drug is limited to articles that
are administered to man e ither internally or externally. Alternatively, respondent
argues, even if the [FFDCA]’s “in-tended for use” language does cover the discs,
they must clearly be classified as devices. . . .
We need not stop to parse the language of the [FFDCA]’s definition of drug, for
the District Court found, and the parties do not disagree here, that a literal reading
of the words “intended for use in the . . . cure, mitigation, [or] treatment” of disease
“clearly has application” to the Bacto-Unidisk. Although respondent again urges
that the disc itself does not “treat” a patient in the same way an antibiotic does in
terms of personal application, the disc plays at least some role in the selection of
the appropriate drug. Thus, the essential question for our determination is whether
Congress intended the definition of drug to have the broad coverage the courts below
and the parties agree its words allow. Viewing the structure, the legislative history,
and the remedial nature of the [FFDCA], we think it plain that Congress intended
to define “drug” far more broadly than does the medical profession. The reason for
including a separate, almost parallel, definition of “devices” in the [FFDCA] is, as
the legislative history shows, relevant to congressional intent. It is therefore helpful
to consider both the question of the [FFDCA]’s initial application and the question
of the drug-device dichotomy at the same time.
III.
At the outset, it is clear from § 201 that the word “drug” is a term of art for the
purposes of the [FFDCA], encompassing far more than the strict medical definition
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of that word. If Congress had intended to limit the statutory definition to the medical one, it could have so stated explicitly, or simply have made reference to the official United States Pharmacopoeia (or the National Formulary), as it did in the first
of the three subsections of § 201(g)(1), and let the definition rest there. The historical expansion of the statute’s definition, furthermore, clearly points out Congress’
intention of going beyond the medical usage. The 1906 Food and Drug Act, for
instance, defined “drug” in a rather l imited way to include “all medicines and preparations recognized in the United States Pharmacopoeia or National Formulary for
internal or external use, and any substance or mixture of substances intended to be
used for the cure, mitigation, or prevention of disease of either man or other animals.” As subsequent congressional action clearly indicates, however, the scope of
that original definition has since been greatly enlarged.
The enactment of the [FFDCA] illustrates the expansion of the definition of
drug. One of the changes contemplated in S. 2800, an early version of the [FFDCA],
defined “drug” to include:
(1) all substances and preparations recognized in the United States Pharmacopoeia, Homoeopathic Pharmacopoeia of the United States, or National
Formulary or supplements thereto; and (2) all substances, preparations,
and devices intended for use in the cure, mitigation, treatment, or prevention of disease in man or other animals; and (3) all substances and preparations, other than food, and all devices intended to affect the structure or
any function of the body. [Emphasis on “devices” added by Court.]
Senator Copeland of New York, who sponsored the [FFDCA], remarked about
the inclusion of the word “devices” in his prepared statement introducing S. 2800
as follows:
The present law defines drugs as substances or mixtures of substances
intended to be used for the cure, mitigation, or prevention of disease. This
narrow definition permits escape from legal control of all therapeutic or
curative devices like electric belts, for example. It also permits the escape of
preparations which are intended to alter the structure or some function of
the body, as, for example, preparations intended to reduce excessive weight.
There are many worthless and some dangerous devices and preparations
falling within these classifications. S. 2800 contains ample authority to control them.
The definition was revised in S. 5, 74th Cong., 1st Sess. (1935), to include substances, preparations, and devices in-tended for diagnostic purposes, as well as for
cure, mitigation, treatment, or prevention of disease. As the inclusion of the word
“diagnosis” came before the Senate for consideration, a controversy developed on
the floor, aimed more at the word “devices,” which was not then before the Senate,
than at the word “diagnosis.” Senator Clark contended that it was not proper to
classify devices as drugs, and that diagnostic devices w
 ere so broadly defined as to
make even a bathroom scale a drug:
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If the devices o
 ught to be outlawed, they o
 ught to be outlawed, and I have
no objection to that; but to maintain that a purely mechanical device is a
drug and to be treated as a drug in law and in logic and in lexicography is a
palpable absurdity, in my opinion.
In answer to Senator Clark’s remark that a bathroom scale would be classified as
a drug, Senator Copeland made the following comment:
Mr. President, I desire to state the effect of this amendment. T
 here are on
the market certain electrical devices. A man takes hold of the handles of
the machine, and the indicator spins around. It stops at ‘appendicitis,’ or it
stops at ‘meningitis’ . . . . Such a device is manifestly a fraud upon society.
That is what the amendment is designed to deal with.
As a result of the criticism on the Senate floor, Senator Copeland proposed an
amendment to add a definition of “device” to parallel that of drug, an amendment which was included when the bill was returned to the Senate Committee on
Commerce and later agreed to by the Senate without debate. The ultimate effect
of the various amendments, of course, was still to include devices u
 nder the control of the [FFDCA] for the first time, the goal Senator Copeland had originally
set out to achieve. . . . According to the Chief of the Food and Drug Administration, the reason for providing a separate definition of devices, instead of using
Senator Copeland’s original drug definition, was simply to avoid “the incongruity
of classifying certain devices, such as the electric b
 elt, therapeutic lamps, and so
forth, as drugs. . . .” (Testimony given during hearings held on S. 5 by a subcommittee of the House Committee on Interstate and Foreign Commerce, 74th Cong.,
1st Sess. (1935).) . . . . No practical significance to the distinction between the two
words arose until the pre-market clearance provisions. . . . The excepting clause of
§ 201(g)(1), stating clearly that a drug cannot be a device, was also added in 1938.
The historical expansion of the definition of drug, and the creation of a parallel concept of devices, clearly show, we think, that Congress fully intended that
the [FFDCA]’s coverage be as broad as its literal language indicates — and equally
clearly, broader than any strict medical definition might otherw ise allow. Strong
indications from legislative history that Congress intended the broad coverage the
District Court thought “ridiculous” should satisfy us that the lower courts erred in
refusing to apply the [FFDCA]’s language as written. But we are all the more convinced that we must give effect to congressional intent in view of the well-accepted
principle that remedial legislation such as the Food, Drug, and Cosmetic Act is to
be given a liberal construction consistent with the [FFDCA]’s overriding purpose to
protect the public health, and specifically, § 507’s purpose to ensure that antibiotic
products marketed serve the public with “efficacy” and “safety.” Cf. United States v.
Sullivan, 332 U.S. 689 (1948); United States v. Dotterweich, 320 U.S. 277 (1943).
IV.
Respondent’s alternative contention, that even if its product does fall within
the purview of the [FFDCA], it is plainly a “device” and therefore by definition
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necessarily not a “drug,” must also be rejected, we believe, in light of the foregoing analysis. At the outset, it must be conceded that the language of the statute
is of little assistance in determining precisely what differentiates a “drug” from
a “device”: to the extent that both are intended for use in the treatment, mitigation and cure of disease, the former is an “article” and the latter includes “instruments,” “apparatus,” and “contrivances.” Despite the obvious areas of overlap in
definition, we are not entirely without guidance in determining the propriety of
the Secretary’s decision below, given the overall goals of the [FFDCA] and its legislative history.
More specifically, as we have previously held in an analogous situation where the
statute’s language seemed insufficiently precise, the “natural way” to draw the line
“is in light of the statutory purpose.” Since the patient w
 ill tend to derive less benefit
and perhaps some harm from a particular antibiotic if, though the drug itself was
properly batch-tested, it was not the proper antibiotic to use, it was entirely reasonable for the Secretary to determine that the discs, like the antibiotics they serve, are
drugs and similarly subject to pre-clearance certification u
 nder § 507. An opposite
conclusion might undercut the value of testing the antibiotics themselves, for such
testing would be a useless exercise if the wrong drug were ultimately administered,
even partially as the result of an unreliable disc.
Furthermore, the legislative history, read in light of the statute’s remedial purpose, directs us to read the classification “drug” broadly, and to confine the device
exception as nearly as is possible to the types of items Congress suggested in the
debates, such as electric b
 elts, quack diagnostic scales, and therapeutic lamps, as well
as bathroom weight scales, shoulder braces, air conditioning units, and crutches. . . . 
Finally, we are supported in the decision to uphold the FDA’s determination that
the sensitivity discs fall u
 nder the coverage of the [FFDCA] and specifically u
 nder
the drug provision thereof by the knowledge that the classification of these discs as
drugs may not be as contrary to common medical usage as the District Court and
respondent would have us believe.
In upholding the Secretary’s construction of the [FFDCA], we are not unmindful
of our warning that “in our anxiety to effectuate the congressional purpose of protecting the public, we must take care not to extend the scope of the statute beyond
the point where Congress indicated it would stop.” 62 Cases of Jam v. United States,
340 U.S. 593 (1951). Our holding here simply involves an obvious corollary to that
principle, that we must take care not to narrow the coverage of a statute short of the
point where Congress indicated it should extend.
Reversed.
Mr. Justice DOUGLAS, being of the view that an antibiotic sensitivity disc used
by physicians to aid them in determining what antibiotic drug, if any, to give to a
patient, is a “device” as defined in § 201(h) of the [FFDCA], not a “drug” as defined
in § 201(g), would affirm the judgment.
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E. Key Points
• FDA is currently based in the Department of Health and H
 uman Serv ices.
However, it has a complex organizational history. It has previously been housed
in other Cabinet-level departments. It has at times acquired new responsibilities from other agencies and it has at times had some of its responsibilities
transferred to other agencies.
• Product categories are the basis of almost all FDA regulation. The basic categories addressed in this book are food, food additives, dietary supplements,
drugs, animal drugs, medical devices, combination products, biologics, HCT/
Ps (human cells, tissues, and cellular and tissue-based products), cosmetics,
color additives, and tobacco products. There are other categories, but these are
less critical to a basic understanding of food and drug regulation.
•	There are inevitable disputes about which product category is the correct fit
for a particular product. These disputes can be tremendously important, as
the regulatory requirements differ dramatically among the different product
categories.
• The different regulatory requirements are most significant with respect to
marketing authorization (see Chapter 4).
• Products in some categories must undergo rigorous FDA review before
they can be marketed in the United States.
• Products in other categories can be marketed without any requirement for
FDA authorization before marketing begins.

